The Abiomed Inc (NSQ:ABMD) share price is currently trading at 275.89. But given the volatile market conditions and uncertain economic outlook, the question now is what the future holds for it. To try and predict where the Abiomed Inc...
ABMD — Abiomed Share Price
0.000.00%
Last Trade - 00:00HealthcareBalancedLarge CapHigh Flyer
- $14.91bn
- $14.39bn
- $935.26m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 68.94 | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Mar | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 445.3 | 593.75 | 769.43 | 840.88 | 847.52 | 1,042.92 | 1,198.84 | 20.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +37.34 | +149.64 | +92.65 | -19.61 | +9.43 | -11.25 | +22.82 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for ABMD
Given that widespread uncertainty in the stock market is likely to endure for the rest of 2020 and beyond, it pays to know that you're investing in high-quality stocks, rather than speculative ones. This means safe, profitable companie...
Profile Summary
ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.
Directors
- Michael Minogue CHM (54)
- Todd Trapp (49)
- David Weber (58)
- Marc Began (53)
- Michael Howley (56)
- Andrew Greenfield VPR (47)
- Dorothy Puhy LED (68)
- Paula Johnson
- Myron Rolle
- Jeannine Rivet (72)
- Eric Rose IND (70)
- Martin Sutter (65)
- Paul Thomas (65)
- Christopher Van Gorder (67)
- Last Annual
- March 31st, 2021
- Last Interim
- June 30th, 2021
- Incorporated
- June 4th, 1987
- Public Since
- July 29th, 1987
- No. of Shareholders
- 357
- No. of Employees
- 1,725
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 45,380,233
- Address
- 22 CHERRY HILL DR, DANVERS, 01923-2575
- Web
- http://www.abiomed.com/
- Phone
- +1 9787775410
- Auditors
- Deloitte & Touche LLP
Latest News for ABMD
Upcoming events for ABMD
Q2 2022 ABIOMED Inc Earnings Release
Similar to ABMD
ACCURAY ORD
NASDAQ Global Select Market
ACUTUS MEDICAL ORD
NASDAQ Global Select Market
AKOYA BIOSCIENCES ORD
NASDAQ Global Select Market
BRUKER ORD
NASDAQ Global Select Market
CERNER ORD
NASDAQ Global Select Market
FAQ
What is the Abiomed share price?
As of Today at 19:54 UTC, shares in Abiomed are trading at $328.56. This share price information is delayed by 15 minutes.
How has the Abiomed share price performed this year?
Shares in Abiomed last closed at $328.56 and the price had moved by +6.14% over the past 365 days. In terms of relative price strength the Abiomed share price has underperformed the S&P500 Index by -19.47% over the past year.
What are the analyst and broker recommendations for Abiomed?
The overall consensus recommendation for Abiomed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Abiomed dividend yield?
Abiomed does not currently pay a dividend.
Does Abiomed pay a dividend?
Abiomed does not currently pay a dividend.
When does Abiomed next pay dividends?
Abiomed does not currently pay a dividend.
How do I buy Abiomed shares?
To buy shares in Abiomed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Abiomed?
As of the previous close price of $328.56, shares in Abiomed had a market capitalisation of $14.91bn.
Where are Abiomed shares listed?
Here are the trading details for Abiomed:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ABMD
What kind of share is Abiomed?
Based on an overall assessment of its quality, value and momentum Abiomed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Abiomed share price forecast for 2021?
The analyst consensus target price for shares in Abiomed is $387.33. That is 17.89% above the last closing price of $328.56.
Analysts covering Abiomed currently have a consensus Earnings Per Share (EPS) forecast of $4.38 for the next financial year.
What is the trend in the Abiomed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abiomed. Over the past six months, its share price has underperformed the S&P500 Index by -10.8%.
As of the last closing price of $328.56, shares in Abiomed were trading +6.85% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Abiomed PE Ratio?
The Abiomed PE ratio based on its reported earnings over the past 12 months is 69.54. The shares last closed at $328.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Abiomed?
Abiomed's management team is headed by:
- Michael Minogue - CHM
- Todd Trapp -
- David Weber -
- Marc Began -
- Michael Howley -
- Andrew Greenfield - VPR
- Dorothy Puhy - LED
- Paula Johnson -
- Myron Rolle -
- Jeannine Rivet -
- Eric Rose - IND
- Martin Sutter -
- Paul Thomas -
- Christopher Van Gorder -
Who are the major shareholders of Abiomed?
We do not have data on Abiomed's shareholders